Current Neurology and Neuroscience Reports

, Volume 3, Issue 1, pp 86–92 | Cite as

Medication-induced peripheral neuropathy

  • Louis H. Weimer


Although not very common, medication-induced neuropathy is a treatable condition and, therefore, is important to identify. Medications continue to grow in number and expand in usage; consequently, toxic neuropathy continues to be relevant to neurologists. Many agents have toxicities that are tolerated because the treatments are necessary, such as therapies for HIV and malignancy. Additional agents to prevent or ameliorate the toxic neuropathy are being sought and trials are ongoing. Certain patients, however, may be at high risk for peripheral nerve toxicity due to genetic factors or another underlying neuropathy. Newer drug-delivery methods, such as viral transfection, may produce less toxicity in the future. The underlying pathomechanisms remain incompletely elucidated; however, apoptosis is emerging as an important final pathway in some forms of toxic neuropathy. Although most cases demonstrate acute or subacute onset after exposure, recent experiences with statin drugs raise the possibility of occult toxic causes of chronic idiopathic neuropathy.


Neuropathy Nerve Growth Factor Peripheral Neuropathy Thalidomide Suramin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jain KK: Drug-induced peripheral neuropathies. In Drug-induced Neurological Disorders, edn 2. Edited by Jain KK. Seattle: Hogrefe & Huber; 2001:263–294.Google Scholar
  2. 2.
    Chaudhry V, Chaudhry M, Crawford TO, Griffin JW: Toxic neuropathy in patients with pre-existing neuropathy [abstract]. Neurology2002, 58(suppl 3):A19.Google Scholar
  3. 3.
    Graf WD, Chance PF, Lensch MW, et al.: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996, 77:1356–1362.PubMedCrossRefGoogle Scholar
  4. 4.
    Lotti M: Age-related sensitivity of the nervous system to neurotoxic insults. Toxicol Lett 2002, 127:183–187.PubMedCrossRefGoogle Scholar
  5. 5.
    Harland CC, Steventon GB, Marsden JR: Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995, 49:1–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang M, Culver DG, Glass JD: The gene for slow Wallerian degeneration (Wld(s)) is also protective against vincristine neuropathy. Neurobiol Dis 2001, 8:155–161.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang MS, Fang G, Culver DG, et al.: The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann Neurol 2001, 50:773–779. Important example of uncovering a specific example of genetic susceptibility to toxic neuropathy and early attempt to apply therapeutically in an in vitro model.PubMedCrossRefGoogle Scholar
  8. 8.
    Windebank AJ: Chemotherapeutic neuropathy. Curr Opin Neurol 1999, 12:565–571.PubMedCrossRefGoogle Scholar
  9. 9.
    Gill JS, Windebank AJ: Cisplatin-induced apoptosis in rat dorsal root ganglia neurons is associated with attempted entry in the cell cycle. J Clin Invest 1998, 101:2842–2850.PubMedCrossRefGoogle Scholar
  10. 10.
    Krarup-Hansen A, Rietz B, Krarup C, et al.: Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropath Appl Neurobiol 1999, 25:29–40.CrossRefGoogle Scholar
  11. 11.
    Makhalova J, Katsarava Z, Liedert B, et al.: Cisplatin-induced neurotoxicity: formation and repair of specific cisplatin-DNA lesions in different cell types of nervous tissue in wild type and XPC-knockout mice [abstract]. Neurology 2002, 58(suppl 3):A19.Google Scholar
  12. 12.
    Krarup-Hansen A, Fugleholm K, Lelweg-Larsen S, et al.: Examination of distal involvement in cisplatin-induced neuropathy in man. Brain 1993, 116:1017–1041.PubMedCrossRefGoogle Scholar
  13. 13.
    Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Cliffer KD, Siuciak JA, Carson SR, et al.: Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998, 43:46–55.PubMedCrossRefGoogle Scholar
  15. 15.
    Dina OA, Chen X, Reichling D, Levine JD: Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001, 108:507–515.PubMedCrossRefGoogle Scholar
  16. 16.
    Boyle FM, Wheeler HR, Shenfield GM: Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neuro-oncol 1999, 41:107–116.CrossRefGoogle Scholar
  17. 17.
    Gelmon K, Eisenhauer E, Bryce C, et al.: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999, 17:3038–3044.PubMedGoogle Scholar
  18. 18.
    Openshaw H, Slatkin N, Beamon K, et al.: The effect of amifostine on peripheral neuropathy after high dose paclitaxel [abstract]. Neurology 2002, 58(suppl 3):A50.Google Scholar
  19. 19.
    Smyth JF, Bowman A, Perren T, et al.: Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of doubleblind randomized trial. Ann Oncol 1997, 8:569–573.PubMedCrossRefGoogle Scholar
  20. 20.
    Cascinu S, Catalano V, Cordella L, et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478–3483.PubMedCrossRefGoogle Scholar
  21. 21.
    Roberts JA, Jenison EL, Kim K, et al.: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997, 67:172–177.PubMedCrossRefGoogle Scholar
  22. 22.
    Chattopadhyay M, Wolfe D, Huang S, et al.: In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002, 51:19–27. Avoided limitations of systemic administration by direct dorsal root ganglion delivery through disabled herpes-simplex virus in live rats. Neurotrophin-3 severely attenuated pyridoxine toxicity without measurable serum levels.PubMedCrossRefGoogle Scholar
  23. 23.
    Pradat PF, Finiels F, Kennel P, et al.: Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther 2001, 12:367–375.PubMedCrossRefGoogle Scholar
  24. 24.
    Boyle FM, Beatson C, Monk R, et al.: The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001, 48:429–434.PubMedCrossRefGoogle Scholar
  25. 25.
    Vahdat L, Papadopoulos K, Lange D, et al.: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001, 7:1192–1197.PubMedGoogle Scholar
  26. 26.
    Campana WM, Eskeland N, Calcutt NA, et al.: Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998, 19:237–244.PubMedGoogle Scholar
  27. 27.
    Sano M: Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drug on cultured embryonic sensory neurons. Neuropharmacology 2001, 40:947–953.PubMedCrossRefGoogle Scholar
  28. 28.
    Russell JW, Gill JS, Sorenson EJ, et al.: Suramin-induced neuropathy in an animal model. J Neurol Sci 2001, 192:71–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Chaudhry V, Eisenberger MA, Sinibaldi VJ, et al.: A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039–2052.PubMedCrossRefGoogle Scholar
  30. 30.
    Soliven B, Dhand UK, Kobayashi K, et al.: Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 1997, 20:83–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Gill JS, Windebank AJ: Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 1998, 5:876–883.PubMedCrossRefGoogle Scholar
  32. 32.
    Gill JS, Windebank AJ: Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion. Neuroscience 1998, 87:855–860.PubMedCrossRefGoogle Scholar
  33. 33.
    Jacobs MG: HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 1994, 120:970.PubMedGoogle Scholar
  34. 34.
    Jeppesen U, Gaist D, Smith T, Sindrup SH: Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999, 54:835–838.PubMedCrossRefGoogle Scholar
  35. 35.
    Phan T, McLeod JG, Pollard JD, et al.: Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995, 58:625–628.PubMedCrossRefGoogle Scholar
  36. 36.
    Gaist D, Jeppesen U, Andersen M, et al.: Statins and risk of polyneuropathy: a case-control study. Neurology 2002, 58:1333–1337. Well-designed study applying newer methods to express neurotoxicity risk. The researchers tapped governmental records to quantify the small but significant numbers. Raises question of unsuspected medication-induced basis of some idiopathic neuropathy. Best evidence to date of neuropathy link to statins.PubMedGoogle Scholar
  37. 37.
    Dalakas MC: Peripheral neuropathy and antiretroviral drugs. J Periph Nerv Syst 2001, 6:14–20.CrossRefGoogle Scholar
  38. 38.
    Coté HC, Brumme ZL, Craib KJ, et al.: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346:811–820.PubMedCrossRefGoogle Scholar
  39. 39.
    Lewis W, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 1995, 1:417–422.PubMedCrossRefGoogle Scholar
  40. 40.
    Moyle G: Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000, 8:911–936.CrossRefGoogle Scholar
  41. 41.
    Brinkman K, Smeitink JA, Romijn JA, Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy-related lipodystrophy. Lancet 1999, 354:1112–1115.PubMedCrossRefGoogle Scholar
  42. 42.
    Pardo CA, McArthur JC, Griffin JW: HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001, 6:21–27.PubMedCrossRefGoogle Scholar
  43. 43.
    Anderson TD, Davidovich A, Feldman D, et al.: Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab Invest 1994, 70:724–739.PubMedGoogle Scholar
  44. 44.
    Berger AR, Arezzo JC, Schaumburg HH, et al.: 2′, 3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993, 43:358–362.PubMedGoogle Scholar
  45. 45.
    Williams D, Geraci A, Simpson M: AIDS and AIDS-treatment neuropathies. Curr Neurol Neurosci Rep 2001, 1:533–538.PubMedCrossRefGoogle Scholar
  46. 46.
    Martin C, Solders G, Sonnerborg A, et al.: Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000, 54:2120–2127. Study demonstrated that lowering RNA viral load through antiretroviral therapy can improve overall sensory function measures, regardless of whether neuropathy-inducing drugs were taken or not.PubMedGoogle Scholar
  47. 47.
    Moyle GJ, Sadler M: Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Safety 1998, 19:481–494.PubMedCrossRefGoogle Scholar
  48. 48.
    Maschke M, Kastrup O, Esser S, et al.: Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000, 69:376–380.PubMedCrossRefGoogle Scholar
  49. 49.
    Scarpini E, Sacilotto G, Baron P, et al.: Effect of acetyl-Lcarnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997, 2:250–252.PubMedGoogle Scholar
  50. 50.
    Simpson DM, Katzenstein D, Haidich B, et al.: Plasma carnitine in HIV-associated neuropathy. AIDS 2001, 15:2207–2208.PubMedCrossRefGoogle Scholar
  51. 51.
    McArthur JC, Yiannoutsos C, Simpson DM, et al.: A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology 2000, 54:1080–1088.PubMedGoogle Scholar
  52. 52.
    Schifitto G, Yiannoutsos C, Simpson DM, et al.: Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001, 57:1313–1316.PubMedGoogle Scholar
  53. 53.
    Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001, 57:365–376.PubMedCrossRefGoogle Scholar
  54. 54.
    Teo S, Evans M, Ehrhart J, et al.: Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. Hum Exp Toxicol 2000, 19:615–622.PubMedCrossRefGoogle Scholar
  55. 55.
    Molloy FM, Floeter MK, Syed NA, et al.: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001, 24:1050–1057.PubMedCrossRefGoogle Scholar
  56. 56.
    Lagueny A, Rommel A, Vignolly B, et al.: Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 1994, 9:837–844.CrossRefGoogle Scholar
  57. 57.
    Rao DG, Kane NM, Oware A: Thalidomide neuropathy: role of F-wave monitoring. Muscle Nerve 2000, 23:1301–1302.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Louis H. Weimer
    • 1
  1. 1.Neurological Institute of New YorkNew YorkUSA

Personalised recommendations